

1 **Chronic Overlapping Pain Conditions and Nociceptive Pain**

2 Keira J.A. Johnston^{1*}, Rebecca Signer², Laura M. Huckins^{1**}

3 1. Department of Psychiatry, Yale School of Medicine, Yale University, New Haven,
4 CT 06511, USA

5 2. Department of Genetic and Genomic Sciences, Icahn School of Medicine at
6 Mount Sinai, New York City, NY 10029, USA

7 3. Corresponding authors. *keira.johnston@yale.edu **laura.huckins@yale.edu

8

9

10 **Abstract**

11 Chronic Overlapping Pain Conditions (COPCs) are a subset of chronic pain conditions
12 commonly comorbid with one another and more prevalent in women and assigned
13 female at birth (AFAB) individuals. Pain experience in these conditions may better fit
14 with a new mechanistic pain descriptor, nociplastic pain, and nociplastic type pain may
15 represent a shared underlying factor among COPCs. We applied GenomicSEM
16 common-factor genome wide association study (GWAS) and multivariate transcriptome-
17 wide association (TWAS) analyses to existing GWAS output for six COPCs in order to
18 find genetic variation associated with nociplastic type pain, followed by genetic
19 correlation (linkage-disequilibrium score regression), gene-set and tissue enrichment
20 analyses. We found 24 independent single nucleotide polymorphisms (SNPs), and 127
21 unique genes significantly associated with nociplastic type pain, and showed nociplastic
22 type pain to be a polygenic trait with significant SNP-heritability. We found significant
23 genetic overlap between multisite chronic pain and nociplastic type pain, and to a
24 smaller extent with rheumatoid arthritis and a neuropathic pain phenotype. Tissue
25 enrichment analyses highlighted cardiac and thyroid tissue, and gene set enrichment
26 analyses emphasized potential shared mechanisms in cognitive, personality, and
27 metabolic traits and nociplastic type pain along with distinct pathology in migraine and
28 headache. We use a well-powered network approach to investigate nociplastic type
29 pain using existing COPC GWAS output, and show nociplastic type pain to be a
30 complex, heritable trait, in addition to contributing to understanding of potential
31 mechanisms in development of nociplastic pain.

32

33 **Background**

34 Chronic pain can be defined as pain that persists 3+ months¹ and is a main symptom of
35 many conditions as well as being associated with injury and surgery. Chronic pain can
36 also be studied as a complex disease trait as evidenced by large recent genome wide
37 association studies (GWAS)²⁻⁷. Recently, the International Association for the Study of
38 Pain (IASP) also redefined pain and ‘chronic primary pain’ codes for the International
39 Classification of Diseases 11th Edition (ICD-11)⁸⁻¹⁰. More than 1 in 5 US adults
40 experience chronic pain¹¹, and chronic pain is associated with high socioeconomic and
41 quality of life burden^{1,12}, and despite genetic studies into chronic pain as a disease trait,
42 and on conditions where chronic pain is a prominent symptom, mechanisms of
43 development of chronic pain are not fully understood.

44

45 Neuropathic and nociceptive pain¹³ are used to categorize pain and chronic pain
46 according to suspected or confirmed underlying mechanism(s). Neuropathic pain is
47 defined as being caused by lesions or disease in the somatosensory nervous system,
48 and nociceptive pain, designed to directly contrast neuropathic pain, is defined as pain
49 arising from actual or threatened damage to non-neural tissue (in the context of a
50 normally functioning somatosensory nervous system). However, pain experienced in the
51 context of many different chronic pain conditions may not fit with these two descriptors –
52 Chronic Overlapping Pain Conditions (COPCs)¹⁴⁻¹⁶ may represent a subset of chronic
53 pain conditions where pain experiences very often diverge from nociceptive/
54 neuropathic or a mixed nociceptive/ neuropathic pain state. COPCs are a subset of
55 chronic pain conditions commonly comorbid with one another and more prevalent in

56 people assigned female at birth (AFAB). The United States congress and the National
57 Institutes of Health (NIH) listed ten conditions as COPCs; myalgic encephalitis/ chronic
58 fatigue syndrome (ME/CFS), vulvodynia, temporomandibular disorders, irritable bowel
59 syndrome (IBS), interstitial cystitis/ painful bladder syndrome, fibromyalgia,
60 endometriosis, chronic tension-type headache, chronic migraine headache, and chronic
61 low-back pain. In these conditions, there may not be actual or threatened tissue
62 damage or lesion/ disease at the somatosensory nervous system (e.g., fibromyalgia), or
63 if features of nociceptive/ neuropathic pain are present they do not fully capture the pain
64 experience (e.g., chronic low back pain). A proposed third mechanistic pain descriptor,
65 'nociplastic pain', added to IASP terminology¹³ in 2017 may better capture features of
66 pain in COPCs¹⁴.

67
68 Nociplastic pain is defined as pain arising from altered nociception in the absence of
69 clear lesion/ disease of the somatosensory nervous system and/or absence of actual or
70 threatened tissue damage. Pain in COPCs, where nociplastic pain could be the
71 underlying mechanism (or main underlying mechanism if a mixed pain state is
72 suspected), may fit better with this description as many COPCs are not associated with
73 neural/ non-neural tissue damage (e.g., fibromyalgia), or if disease and tissue damage
74 are present pain is often non-proportional to tissue damage and can be diffuse
75 throughout the body beyond diseased tissue sites (e.g., endometriosis, chronic low back
76 pain). Nociplastic pain is also associated, compared to nociceptive or neuropathic pain,
77 with greater risk of CNS-related symptoms such as fatigue, changes in cognition and
78 memory, depression, anxiety, and sleep issues as also commonly seen in COPCs¹⁵.

79
80 These features of COPCs, combined with the fact they are commonly comorbid with
81 one another, may suggest that nociplastic type pain is an underlying shared factor
82 across COPCs. Even in COPCs where a mixed pain state with nociceptive pain (i.e.,
83 where tissue damage may be present) such as endometriosis, studies have shown that
84 nociplastic pain contributes significantly to pain experience, and is associated with
85 severity of pain independent of surgical procedures, amount of endometriosis, body
86 mass index, and age ¹⁷. Previous studies also suggest COPCs could be viewed as a
87 single “lifelong” disease that “manifests in different bodily regions over time” ¹⁸. There
88 are epidemiological studies of pelvic pain conditions (e.g., MAPP ^{19,20}), but there are no
89 GWAS of vulvodynia, chronic pelvic pain, or bladder pain syndrome/ IC. In addition,
90 there are to date no sufficiently large studies with both genotyping and questionnaire
91 data designed specifically to ascertain nociplastic pain (such as the Central
92 Sensitization Inventory ²¹ or Nociplastic-Based Fibromyalgia Features tool ²²). However,
93 large-scale GWAS for several other COPCs are available, and can be studied as a
94 network to uncover genetic variation associated with nociplastic-type pain as an
95 underlying factor in all COPCs.

96
97 Chronic pain conditions can be highly stigmatized ^{23–27} – this is likely even more
98 common in COPCs due to a lack of or disproportionate-to-pain-level presence of tissue
99 or nerve damage ^{28–30}, and higher prevalence of COPCs in women and AFAB people
100 ^{23,31}. Understanding mechanisms of chronic pain that are not due to, or cannot be fully
101 explained by, nervous system damage or dysfunction or tissue damage (i.e., nociplastic

102 pain) will contribute to legitimizing the pain experience in COPCs. In addition, finding
103 genetic variation associated with nociplastic pain could inform new treatment
104 approaches in COPCs, conditions where many existing pharmaceutical and surgical
105 treatments can be less effective ³² or even actively worsen pain ³³ compared to use in
106 nociceptive/ neuropathic pain.

107

108 **Methods**

109

110 **GWAS summary statistics**

111 GWAS summary statistics for 6 chronic overlapping pain condition (COPC) traits were
112 obtained through publicly available downloads, requests made directly to study authors,
113 or through data request to FinnGenn (release R9, May 2023). Traits, sample sizes, and
114 sources are summarized in Table 1, and include chronic widespread pain ², low back
115 pain ³⁴, broad headache ³⁵, temporomandibular joint disorder ³⁶, and irritable bowel
116 syndrome ³⁷. We opted not to include migraine or ME/CFS summary statistics. With
117 ME/CFS ³⁸ this is due to sample size being too small for successful completion of the
118 multivariable LDSC step of GenomicSEM common-factor GWAS analysis (Ncase = 427,
119 Ncontrol = 972), and because genotyping in this study was performed using the Illumina
120 ImmunoChip array (i.e., not whole-genome genotyping, but a specialized assay focused
121 on immune-relevant SNPs). For migraine, a significant proportion of the 'broad
122 headache' GWAS case participants are likely migraineurs and/or have both tension-type
123 headache and migraine, therefore including the broad headache GWAS but not

124 migraine GWAS allows for capturing a fuller spectrum of headache and migraine-
125 associated genetic variation, without over-representation of migraine.

126 For each trait excluding endometriosis, GWAS samples are at least partially, and in
127 some cases completely, comprised of UK Biobank participants and samples may
128 overlap –sample overlap is permitted and does not statistically bias GenomicSEM
129 analyses^{39,40}.

130

131 Table 1

132

133 **Common factor GWAS**

134 GenomicSEM was used to carry out a common-factor GWAS. First, we prepared
135 (munged) GWAS summary statistics using ‘munge’ function included in GenomicSEM.
136 Sum of effective sample sizes was calculated for low back pain (LBP) and IBS, as these
137 represented GWAS meta-analyses of case-control phenotypes⁴¹. Briefly, variants with
138 info values ≤ 0.9 , minor allele frequency (MAF) ≤ 0.01 , that were not SNPs with
139 missing values, that were strand ambiguous, those with duplicated rsIDs, those without
140 a match in the HapMap 3 SNP file used for quality control, and those with mismatched
141 allele labels compared to the HapMap 3 SNP file were removed. Next, multivariable
142 linkage disequilibrium (LD)- score regression was carried out to produce matrices used
143 in the common-factor GWAS step. GenomicSEM ‘sumstats’ function was used for a
144 final preparation step, jointly processing the GWAS summary statistics files for each of
145 the 6 traits included in the analysis. This function merges across all summary statistics
146 using listwise deletion, performs quality control (including backing out logistic betas,

147 checking for allele mismatches, missing data, and duplicate variants), and merges with
148 the reference SNP file. Output from multivariable LD-score regression and from
149 GenomicSEM ‘sumstats’ is taken forward to common factor GWAS using GenomicSEM
150 ‘commonFactorGWAS’ function. Our chosen common-factor model, where the single
151 latent factor represents ‘nociplastic type pain’, is shown in Figure 1.

152

153 **Figure 1**

154

155 First, we fitted the common-factor GWAS model without SNP effects and noted loadings
156 of each trait onto the singular factor (Figure 1). These were significant (Table 2, $p <$
157 0.05) and model fitting was successful, so we proceeded to fitting the model including
158 SNP effects with ‘smooth_check=T’. We note that TMJ variance standard error is very
159 large (Figure 1, $SE = 3.8$), likely due to the small case number in the TMJ GWAS, but
160 factor loading was significant (Table 2, 0.69 , $p < 0.05$) so we elected to include TMJ in
161 this model. Output produced from the above model is equivalent to GWAS summary
162 statistics (magnitude of association between each SNP and a trait of interest) for the
163 latent factor onto which the 6 traits load – which we describe as nociplastic-type pain.
164 Next, we calculate an estimated sample size for the ‘GWAS’ of nociplastic-type pain
165 according to instruction provided on the GenomicSEM github, first reserving SNP
166 results for SNPs with $MAF \leq 0.4$ and ≥ 0.1 , and then calculating \hat{N} according to the
167 formula for each SNP:

$$\frac{1}{(2 * MAF * (1 - MAF)) * SE^2}$$

168

Equation 1: Formula to estimate per-SNP sample size for SNPs included in common-factor GWAS

169

170

171 Taking the mean of this set of values then gives \hat{N} . For nociplastic-type pain \hat{N}

172 =578,561.3 (where this sample size is necessary in calculations e.g., LD-score

173 regression analyses for genetic correlation, we use the value 578,561).

174 Table 2

175

176 **Defining significant, independent SNPs**

177 Common-factor GWAS output (nociplastic type pain summary statistics) was then taken

178 forward and analyzed within FUMA (Functional Mapping and Annotation of Genome-

179 Wide Association Studies)⁴², a web-based suite of tools for downstream GWAS

180 analyses. Genome-wide significant, independent SNPs were defined using FUMA as

181 SNPs associated with nociplastic pain factor ($p < 5 \times 10^{-8}$) and independent from one

182 another ($r^2 < 0.6$).

183

184 **LD-score Regression**

185 We used 'ldsc'^{40,43} to estimate SNP-heritability of nociplastic-type pain, and to estimate

186 genetic correlation between nociplastic-type pain and three pain-related phenotypes;

187 multisite chronic pain (MCP), a measure of number of chronic pain sites, rheumatoid

188 arthritis, a chronic pain condition that is not usually considered a COPC and where pain

189 for a majority of individuals is likely mainly nociceptive/ inflammatory^{44,45}, and a

190 neuropathic pain phenotype⁴⁶.

191

192 **Multisite chronic pain vs nociplastic-type pain**

193 We obtained summary statistics for GWAS of multisite chronic pain (MCP)³, a general
194 chronic pain phenotype previously found to be heritable, polygenic, and significantly
195 associated with gene expression changes in the brain through download from University
196 of Glasgow Enlighten (research data repository). MCP summary statistics were munged
197 as previously described, using ‘ldsc’ package, as was common factor GWAS output for
198 nociplastic-type pain. We then carried out LD-score regression, estimating genetic
199 correlation between MCP and nociplastic-type pain.

200

201 **Rheumatoid arthritis vs nociplastic-type pain**

202 We obtained rheumatoid arthritis GWAS summary statistics from a recent large GWAS
203 (N = 311, 292)⁴⁷ from GWAS Catalog⁴⁸. As previously described and again using
204 ‘ldsc’, we calculated genetic correlation between nociplastic type pain and rheumatoid
205 arthritis.

206

207 **Neuropathic vs nociplastic-type pain**

208 We obtained GWAS summary statistics for a study on neuropathic pain susceptibility
209 ($N_{\text{effective}} = 16,311.72$) by request to the study authors⁴⁶, using ‘ldsc’ as previously
210 described to calculate genetic correlation between nociplastic-type pain and neuropathic
211 pain.

212

213 **Multivariate Transcriptome-Wide Association Study**

214 An extension of GenomicSEM common-factor GWAS is multivariate (common-factor)
215 TWAS. Here, FUSION TWAS⁴⁹ output for each of the 6 COPCs serves as input (as
216 GWAS summary statistics did for common-factor GWAS in GenomicSEM common-
217 factor GWAS). We performed TWAS in each of the 6 COPC traits using GWAS
218 summary statistics and the FUSION package and scripts, and using pre-computed
219 predictive models for all 49 Genotype-Tissue Expression project (GTEx)⁵⁰ v8 tissues⁵¹.
220 We used models including genes with significant heritability and with weights calculated
221 using all genetic ancestries, as recommended for typical analyses and to increase
222 sensitivity. FUSION output (TWAS summary statistics for each of the 6 COPCs) was
223 prepared using the GenomicSEM 'read_fusion' function, and then taken forward with
224 multivariable LDSC output from previous common-factor GWAS analysis to perform
225 common-factor TWAS.

226

227 Significant gene-tissue association findings were defined at the tissue-wide and
228 experiment-wide level, through Bonferroni multiple testing correction across all tests
229 within a tissue and across all genes tested across all tissues respectively.

230

231 **Specific and Non-Specific Genes**

232 As part of multivariate GWAS and TWAS analyses, a Q (heterogeneity) value is
233 calculated per SNP-trait association (or per gene-tissue-trait association), indicating
234 degree of heterogeneity (i.e., the proportion of gene expression or SNP association
235 effect that is mediated through pathways other than the shared common factor). Genes
236 specific to nociplastic-type pain were identified through subsetting multivariate TWAS

237 output to include genes in significant (tissue-wide) gene-tissue associations and with
238 non-significant Q p values (i.e., non-significant heterogeneity). Non-specific genes were
239 also identified as above but with significant Q p values. Q p values were Bonferroni-
240 corrected for multiple testing within-tissue. ($Qp_{\text{Bonferroni}} = Qp/N$ tests in that tissue).

241

242

243 **Tissue enrichment analyses**

244 We carried out binomial tests of enrichment within our TWAS results to investigate
245 whether certain tissues showed a higher proportion of tissue-wide significant ($P_{\text{Bonferroni}}$
246 < 0.05) associations results than expected by chance, and whether certain tissues
247 showed higher proportion of nominally significant ($P < 0.05$) associations than expected
248 by chance. Genes tested per tissue are available from FUSION predictor models ⁴⁹.

249

250 **Gene-set enrichment analyses**

251 Gene-set enrichment analyses on all tissue wide significant genes, on tissue wide
252 significant and specific genes ($Qp_{\text{Bonferroni}} > 0.05$), and on tissue wide significant non-
253 specific genes ($Qp_{\text{Bonferroni}} < 0.05$) was carried out using FUMA, with all genes tested in
254 multivariate TWAS and with recognized Ensembl gene ID as background ($N = 26455$
255 genes).

256

257

258 **Results**

259

260 **Common-factor GWAS**

261 We fitted a common factor GWAS model (including individual SNP effects), using data
262 for six COPC traits (CWP, LBP, endometriosis, TMJ, IBS, and broad headache). This
263 model estimates the size of association between SNPs and a latent common factor
264 (nociplastic type pain), producing results effectively equivalent to a standard GWAS of
265 this unmeasured latent factor. We found a total of 663 SNPs across fifteen GWAS
266 genomic risk loci significantly associated with nociplastic-type pain ($p < 5 \times 10^{-8}$,
267 Figure 2), consisting of 24 independent SNPs. The majority of these SNPs (18/24) have
268 not been previously associated with pain-related traits (Table S2).

269

270 **Figure 2**

271

272 **Heritability and Genetic Correlation**

273 We estimated the SNP-based heritability of the nociplastic type pain trait using output
274 from our GenomicSEM common-factor GWAS. We also estimated genetic correlation
275 between nociplastic type pain and another complex chronic pain trait, multisite chronic
276 pain, between nociplastic type pain and RA, a disease where chronic pain is a common
277 symptom but is likely associated with nociceptive rather than nociplastic pain
278 mechanisms^{44,45}, and between nociplastic-type pain and neuropathic pain. Nociplastic-
279 type pain was found to be significantly heritable (liability scale SNP- $h^2 = 0.025$, SE =
280 0.0014), and was significantly genetically correlated with MCP ($rg = 0.92$, SE= 0.04) and

281 to a much lesser degree with rheumatoid arthritis ($r_g = 0.18$, $SE = 0.04$). Neuropathic
282 and nociplastic-type pain were also significantly genetically correlated ($r_g = 0.79$, $SE =$
283 0.099).

284
285 The LD-score regression intercept values when calculating these genetic correlations
286 was close to 1 (0.97-1.03), suggesting the majority of genomic inflation captured by
287 lambda GC (estimates ranging 1.0025-1.3) is due to polygenicity rather than population
288 structure.

289

290 **Multivariate TWAS**

291 To explore nociplastic type pain at the transcriptomic level and uncover tissue-level
292 gene expression relevant to this trait, we carried out a common-factor TWAS analysis of
293 6 COPC traits using GenomicSEM. We found 819 tissue-wide significant gene-tissue
294 associations consisting of 127 unique genes, across all 49 tested GTEx tissues. As part
295 of multivariate GWAS and TWAS analyses with GenomicSEM, a Q (heterogeneity)
296 value is calculated per association. This value indicates degree of heterogeneity (i.e.,
297 the proportion of gene expression or SNP association effect that is mediated through
298 pathways other than the shared common factor, across the traits included in the model
299 that load onto the common factor). Specific genes were identified through subsetting
300 multivariate TWAS output to include genes in significant (tissue-wide) gene-tissue
301 associations and with non-significant Q p values (i.e., non-significant heterogeneity).
302 Non-specific genes were also identified as above but with significant Q p values. Q p

303 values were Bonferroni-corrected for multiple testing within-tissue. ($Q_{p_{\text{Bonferroni}}} = Q_p/N$
304 tests in that tissue).

305

306 450 of the 819 tissue-wide significant gene-tissue associations showed significant
307 heterogeneity ($Q_{p_{\text{Bonferroni}}} < 0.05$), and the remaining 369 did not ($Q_{p_{\text{Bonferroni}}} > 0.05$).

308 Twenty-eight unique genes showed significant heterogeneity across all tested tissues
309 ($Q_{p_{\text{Bonferroni}}} < 0.05$), and 94 showed non-significant heterogeneity ($Q_{p_{\text{Bonferroni}}} > 0.05$).

310 Five genes showed both significant and non-significant heterogeneity depending on
311 tissue, and were excluded from gene-set enrichment tests of specific/ heterogeneous
312 genes.

313

314 **Tissue enrichment**

315 To determine whether specific tissues showed more or fewer significant TWAS results
316 than expected by chance, we carried out a series of binomial tests for enrichment of
317 significant TWAS results within each tested tissue. We found that 9 of the 49 tested
318 tissues showed a different proportion of significant gene-tissue TWAS findings than
319 expected by chance. Cultured fibroblasts, atrial appendage of the heart, tibial nerve,
320 and thyroid were enriched for significant associations, whereas amygdala, substantia
321 nigra, Epstein-Barr-virus-transformed lymphocytes, terminal ileum of the small intestine
322 and vagina showed significantly fewer significant associations than expected. At the
323 nominal significance level (unadjusted $P < 0.05$), two tissues showed a different
324 proportion of associations than expected by chance – whole blood and skeletal muscle
325 were enriched for significant (unadjusted $P < 0.05$) associations.

326

327 **Gene-set enrichment**

328 To explore potential mechanisms in nociplastic pain that are shared with other complex
329 traits of interest, we performed three sets of gene-set enrichment tests using FUMA.

330 First, we used all unique tissue-wide significant gene findings from multivariate TWAS,
331 then a subset of those findings that showed significant heterogeneity (non-specific
332 genes) and finally a subset with non-significant heterogeneity (specific genes).

333

334 **Tissue-wide significant genes**

335 Of 127 unique genes, 120 had a recognized ensemble gene ID within FUMA and were
336 included in analyses. Eight positional gene sets were enriched (adjusted $p < 0.05$) for
337 nociplastic-type-pain associated genes; chr17q21, chr3p21, chr9q33, chr16q22,
338 chr12q13, chr2q34, chr4q33, and chr1q21. Kyoto Encyclopedia of Genes and Genomes
339 (KEGG) pathway gene set nitrogen metabolism was also enriched for nociplastic pain
340 genes, as was chemical and genetic perturbation gene set 'SU_LIVER' (genes
341 specifically upregulated in the liver). A total of 44 GWAS Catalog traits including
342 cognitive function (adjusted $p = 1.76 \times 10^{-10}$), extremely high intelligence (adjusted $p =$
343 3.3×10^{-9}), sleep duration (adjusted $p = 5.95 \times 10^{-9}$), and headache (adjusted $p = 1.10 \times 10^{-$
344 8) were enriched for nociplastic-type pain genes (Table S3, Figure 3A). Additional gene
345 sets enriched for nociplastic pain genes including microRNA target sets, transcription
346 factor target sets, computational gene sets and cancer gene modules can be found in
347 Table S4.

348

349

350 **Figure 3**

351

352 **Specific genes**

353 90 of 94 tissue-wide significant genes without significant heterogeneity across all
354 tissues where a significant association was found, and with an ensembl gene ID
355 recognized within FUMA were included in this analysis. We found seven positional gene
356 sets to be enriched for specific nociplastic pain genes, including chr3p21, chr9q33,
357 chr16q22, chr2q34, chr4q33, chr12q13, and chr1q21. Chemical and genetic
358 perturbation gene set 'SU_LIVER' (adjusted $p = 4.45 \times 10^{-3}$) was enriched for specific
359 nociplastic pain genes, as was nitrogen metabolism (adjusted $p = 0.01$), and the
360 hallmark gene set fatty acid metabolism (adjusted $p = 0.018$). Additional gene sets
361 enriched for specific nociplastic pain genes are listed at Table S5. We found 28 GWAS
362 Catalog traits enriched for specific nociplastic pain genes (Table S6, Figure 3B),
363 including extremely high intelligence (adjusted $p = 8.02 \times 10^{-10}$), sleep duration (adjusted
364 $p = 1.09 \times 10^{-9}$), regular attendance at a religious group (adjusted $p = 2.77 \times 10^{-9}$), and
365 cognitive function (adjusted $p = 3.08 \times 10^{-7}$).

366 **Non-specific genes**

367 25 of 28 tissue-wide significant genes with significant heterogeneity across tissues
368 where a significant association was found, and with an ensembl gene ID recognized
369 within FUMA were included in this analysis. Positional gene sets chr17q21, and chr6q16
370 were enriched for these non-specific nociplastic pain genes, as were several cancer
371 gene neighborhoods (Table S7) and 9 GWAS Catalog traits including migraine without

372 aura (adjusted $p = 9.31 \times 10^{-7}$), headache (adjusted $p = 1.79 \times 10^{-6}$), and migraine
373 (adjusted $p = 7.63 \times 10^{-5}$) (Table S8, Figure 3C).

374

375 There was no overlap in gene sets enriched for specific and non-specific genes, and
376 migraine and headache gene sets were enriched for non-specific nociplastic-type pain
377 genes only.

378 **Discussion**

379 We carried out common-factor GWAS and TWAS analyses incorporating six COPCs to
380 investigate genetic variation associated with nociplastic type pain, a mechanistic pain
381 descriptor and type of pain likely important across COPCs. This method allows us to
382 find genetic variation associated with nociplastic type pain in the absence of a dataset
383 where genotype data and phenotype information on nociplastic type pain are available
384 together. Furthermore, if nociplastic type pain is a shared factor among COPCs, then
385 our findings are likely relevant to COPCs where GWAS are currently unavailable and/ or
386 could not be included here, such as interstitial cystitis, vulvodynia, and ME/CFS. We
387 found that nociplastic type pain is a moderately heritable trait (observed SNP-h² 0.025)
388 with similar SNP heritability to rheumatoid arthritis (RA liability scale SNP-h² = 0.07,
389 observed SNP-h² = 0.035). Our findings indicate that nociplastic type pain is a complex,
390 polygenic trait, and we found 24 independent SNPs significantly associated with this
391 trait.

392

393 **Nociplastic type pain is genetically correlated with rheumatoid arthritis and MCP**

394 We observed extremely high genetic correlation between nociplastic type pain and MCP
395 ($r_g = 0.92$). Individuals with a non-zero trait value for MCP could as a group be majority
396 composed of individuals with COPCs – to assess this we carried out a series of Fisher's
397 exact tests on counts of COPC ICD10 code occurrences within and outside of MCP
398 'cases' (MCP trait value ≥ 1) in UK Biobank (see Table S9). We found that for ICD10
399 category codes for COPCs that were available in UK Biobank (back pain, post-viral
400 fatigue (ME/CFS), migraine, IBS, endometriosis and tension headache), all were

401 significantly overrepresented in MCP cases compared to those without chronic pain
402 (MCP trait value 0), with the most over-represented COPC being fibromyalgia (OR
403 4.48), considered a prototypical nociplastic pain condition. However, we also tested for
404 enrichment of rheumatoid arthritis (a non-COPC pain condition) cases, and again found
405 significant enrichment (Table S9). This suggests high phenotypic overlap in COPCs and
406 MCP in UK Biobank cannot fully explain high genetic correlation values of our
407 nociplastic pain factor and MCP.

408 Another explanation for high nociplastic pain factor-MCP genetic correlation may be that
409 a large amount of genetic variation associated with the main characteristic of MCP
410 (increasing number of sites of chronic pain) is also captured in a GWAS/ GWAS-
411 equivalent analysis of nociplastic type pain – a recent paper outlining clinical criteria in
412 assessing and grading nociplastic pain lists regional (as opposed to discrete) location
413 and spread of pain as a key characteristic of nociplastic pain⁵². Additionally, diagnostic
414 criteria in RA include (chronic) pain in at least 2 or more large joints, which may
415 generate the significant phenotypic overlap between RA and MCP in UK Biobank –
416 however in RA this ‘increasing number of sites’ characteristic is driven by disease-
417 specific processes, resulting in low genetic correlation between RA and nociplastic pain
418 factor, and between RA and MCP.

419
420 Neuropathic pain was also relatively highly genetically correlated with nociplastic-type
421 pain ($rg = 0.79$) – however this rg value is significantly less than 1, indicating a
422 significant portion of genetic variation is distinct between these two pain traits. In
423 addition, a high degree of genetic correlation between nociplastic type and neuropathic

424 pain, to a greater extent than rg with nociceptive pain types, could be expected. In their
425 recent review on nociplastic pain, Fitzcharles et al emphasize not only how common
426 mixed pain states are (pain with nociceptive/neuropathic/nociplastic features), but that
427 neuropathic features in hip and knee arthritis and low back pain observed in studies
428 predating the concept of nociplastic pain likely represent nociplastic etiology ¹⁴.
429 Neuropathic features of pain in various rheumatic diseases have also been suggested
430 to actually represent nociplastic pain ⁵³.

431

432 **Traits enriched for specific and non-specific nociplastic-type pain genes indicate** 433 **distinct pathology of migraine and headache**

434 Gene set enrichment results showed certain genes significantly contribute to variation in
435 nociplastic pain phenotype, but that a large amount of their influence on COPC traits is
436 not mediated by nociplastic type pain (non-specific genes i.e., genes with significant
437 heterogeneity in genomicSEM analyses). GWAS trait gene sets enriched for such
438 genes included migraine and headache, suggesting involvement of factors outside of
439 nociplastic pain in these traits. Non-nociplastic-type-pain-specific genes were also
440 enriched in trait gene sets for male-pattern baldness (androgenic alopecia) – alopecia,
441 including androgenic alopecia, has been previously associated with drugs that block
442 CGRP (calcitonin gene related peptide), a treatment for acute migraine and migraine
443 prevention ⁵⁴.

444

445 **Potential metabolic and liver related pathology in nociplastic pain**

446 GWAS trait gene sets enriched for specific nociplastic type pain genes included amino
447 acid and acylcarnitine levels. Changes in amino acid levels are associated with
448 fibromyalgia, migraine, osteoarthritis and complex regional pain syndrome⁵⁵. High
449 acylcarnitine levels can indicate disorders in fatty acid metabolism, and diets high in
450 certain fatty acids have been associated with increased allodynia in rodent models, and
451 associated with human chronic pain conditions⁵⁶. Lipids generally are also involved in
452 acute and chronic inflammation⁵⁷ and changes to acylcarnitine metabolism are
453 observed in dementia, certain cancers, heart failure and coronary artery disease⁵⁸.
454 Changes to circulating lipids have also been observed in COPCs including fibromyalgia,
455 headache, migraine, TMD, low back pain and IBS⁵⁹, and cholesterol metabolism in
456 microglia has been linked to neuropathic pain in a rodent model⁶⁰. In addition, certain
457 drug therapies used in treatment for systemic lupus erythematosus and rheumatoid
458 arthritis can disrupt lipid metabolism⁶¹, and experiencing chronic pain is associated with
459 changes in diet that can result in changes in lipid profiles⁶².

460

461 Genes specifically upregulated in liver tissue were also enriched for specific nociplastic
462 type pain genes. Gene findings from TWAS in this study in theory most likely represent
463 gene expression mediating the relationship between genotype and trait – in other words
464 gene expression that is likely genetically regulated and that occurs before development
465 of nociplastic pain. Therefore, changes in the liver associated with nociplastic pain may
466 develop prior to nociplastic pain development.

467

468 Curcuminoids (components of turmeric) have been previously investigated in treatment
469 of neuropathic pain, and previous studies found that a possible mechanism of action in
470 alleviating neuropathic pain was via modulating nitrogen metabolism⁶³. Although
471 ME/CFS summary statistics were not used in this analysis, changes in nitrogen
472 metabolism have been implicated in this condition⁶⁴, and our findings suggest these
473 metabolic changes may not be unique to ME/CFS but instead shared across COPCs
474 through influence on nociplastic pain in particular. Those with ME/CFS have also been
475 found to have altered lipid, acylcarnitine, and amino acid levels compared to non-
476 ME/CFS controls⁶⁵.

477

478 **Positional gene sets enriched for nociplastic type pain genes suggest immune** 479 **and musculoskeletal factors**

480 Positional gene sets associated with specific nociplastic pain genes have also been
481 previously linked to COVID-19 susceptibility and severity (chr3p21,⁶⁶), schizophrenia
482 and bipolar disorder (chr3p21,⁶⁷), and Alzheimer disease in an African American cohort
483 (chr3p21,⁷). Regions in chr9q33 are frequently deleted in certain cancers^{68,69}, and
484 chr16q22 has been previously associated with a rare duplication syndrome
485 accompanied by varying psychiatric disorder symptoms⁷⁰, and with schizophrenia⁷¹. A
486 type of syndactyly (involving fusion of digits and toes) has been associated with chr2q34
487⁷², along with autoimmunity, amyotrophic lateral sclerosis and schizophrenia⁷³, and
488 age-related degeneration in the lumbar spine⁷⁴. Variants in the chr12q13 region have
489 been associated with childhood obesity⁷⁵ and asthma^{76,77}. Finally, chr1q21 has been
490 previously implicated in GWAS of circulating interleukin 6 levels⁷⁸. These findings

491 suggest shared immune and musculoskeletal related etiology in these phenotypes and
492 nociplastic type pain. Other recent studies in the context of pain and long COVID have
493 found that infection can potentially trigger and/or exacerbate existing painful conditions,
494 particularly COPCs including fibromyalgia and ME/CFS, and that those with an existing
495 COPC were more likely to develop long COVID, again suggesting possible immune
496 differences in COPCs ⁷⁹.

497

498 In contrast, positional gene sets enriched for non-specific nociplastic pain genes
499 included chr17q21, where duplication and deletion have previously been associated
500 with syndromes involving distinctive craniofacial features, developmental delay, and
501 cardiac symptoms (Online Mendelian Inheritance in Man (OMIM) accession: 610443,
502 613533), and genes at chr6q16 with cardiac phenotypes ⁸⁰ and cluster headache and
503 migraine ⁸¹.

504 **Tissue enrichment of nociplastic type pain genes highlights thyroid, heart, and**
505 **tibial nerve involvement**

506 Hypothyroidism can both cause pain and worsen pain experienced as part of comorbid
507 chronic pain conditions. Autoimmune disorders including autoimmune hypothyroidism
508 may also be misdiagnosed as fibromyalgia ⁸²⁻⁸⁴. Enrichment of nociplastic type pain
509 gene associations in thyroid may therefore indicate high levels of thyroid involvement in
510 COPCs, or extensive presence of individuals with comorbid (or misdiagnosed)
511 hypothyroidism among COPC GWAS participants, or both.

512

513 Atrial appendages of the heart (left and right) are small pouches located on the front
514 upper surface of the right atrium, and anterior to the left atrium and parallel to the left
515 pulmonary veins. Atrial fibrillation, the most common abnormal heart rhythm in adults,
516 can lead to formation of clots (most commonly in the left atrial appendage) and
517 subsequent stroke⁸⁵⁻⁸⁷. Electrocardiogram abnormalities, particularly atrial fibrillation,
518 have been linked to chronic pain^{88,89}, and with physiological stress associated with
519 chronic illness and major surgery^{90,91}. Chronic pain has also been associated with
520 higher risk of myocardial infarction, death due to cardiovascular event, heart failure, and
521 stroke⁹². Our findings may suggest this atrial fibrillation in particular could be common
522 in nociplastic pain and COPCs, increasing risk for stroke in these patient populations.

523
524 The tibial nerve is one of two terminal branches of the sciatic nerve, providing motor and
525 sensory innervation to almost all of the posterior foot and leg. An ultrasound study
526 comparing participants with fibromyalgia and controls found significant increased cross-
527 sectional area in several nerves, including tibial nerve⁹³. Tarsal tunnel syndrome, a
528 nerve entrapment syndrome analogous to carpal tunnel syndrome in the wrist, was also
529 found to be more common in fibromyalgia patients⁹⁴ – while causes of tarsal tunnel
530 syndrome are likely multifactorial, enlarged tibial nerve diameter may contribute to this
531 nerve entrapment. Neuromodulation involving the tibial nerve (e.g., through
532 percutaneous tibial nerve stimulation) has also been investigated in the treatment of a
533 range of pelvic pain disorders, including IBS, dysmenorrhea, and bladder pain
534 syndrome⁹⁵. One caveat is that tibial nerve is the only peripheral nerve tissue sampled
535 in GTE_x – other peripheral nerve tissues, potentially also representing therapeutic

536 targets in neuromodulation for chronic pain, could potentially be enriched for nociplastic
537 pain gene expression.

538

539 **Conclusions**

540 COPCs are a subset of chronic pain conditions that are commonly comorbid. A third
541 mechanistic pain descriptor, nociplastic pain, may best represent the pain experience of
542 those with COPCs, where tissue and/or nerve damage is often not present. Using
543 existing COPC GWAS data and a network-informed genomics approach, GenomicSEM,
544 we found genetic variation at the SNP, gene expression, and gene-set level associated
545 with nociplastic type pain. We also explored genetic overlap with other chronic pain
546 phenotypes, tissue enrichment of nociplastic pain genes, and differences in genes
547 specific and non-specific to nociplastic-type pain. Our findings indicate distinct
548 pathology in migraine and headache compared to other COPCs and link this distinct
549 pathology with traits such as Parkinson disease, sense of smell, and androgenic
550 alopecia, as well as provide unique genes associated with this pathology. We
551 demonstrate various degrees of genetic overlap between nociplastic type pain and three
552 different pain traits, showing highest overlap with a trait capturing increasing number of
553 pain sites on the body (a key characteristic of nociplastic pain in the literature), and
554 lowest with rheumatoid arthritis, a chronic pain condition where pain mechanisms are
555 considered mostly nociceptive. We also find tissue enrichment relevant to chronic pain
556 comorbidities including stroke and therapies such as peripheral nerve stimulation. Our
557 findings contribute to further understanding mechanisms of nociplastic type pain, and
558 indicate this type of pain is important across COPCs.

559

560 **Supplemental Information**

561 Supplemental information includes 10 tables.

562 **Declaration of Interests**

563 The authors declare no competing interests.

564 **Acknowledgements**

565 KJAJ is supported by NIMH (R01MH118278; R01MH124839). RS and LMH are
566 supported by NIMH (R01MH118278; R01MH124839) and NIEHS (R01ES033630). Data
567 associated with UK Biobank approved application number 18177 was used in this study.
568 We thank the study authors who provided their GWAS summary statistics directly to us.

569 **Web Resources**

570 FUMA: <https://fuma.ctglab.nl/>

571 FUSION and genes tested per tissue: <http://gusevlab.org/projects/fusion/#gtex-v8-multi-tissue-expression>

573 GenomicSEM: <https://github.com/GenomicSEM/GenomicSEM>

574 GWASCatalog: <https://www.ebi.ac.uk/gwas/>

575 LDSC: <https://github.com/bulik/ldsc>

576 **Data and Code Availability**

577 Individual-level data for UK Biobank is available upon approved application to UK
578 Biobank. Code and resources to implement FUSION, GenomicSEM and LDSC are
579 available at the provided web addresses.

580 Common-factor GWAS and multivariate TWAS summary statistics produced as part of
581 this study are available for download <https://doi.org/10.5281/zenodo.8117582>

582 GWAS summary statistics for broad headache, LBP, and neuropathic pain may be
583 available upon request to the respective study authors.

584 GWAS summary statistics for endometriosis are available from

585 https://www.finngen.fi/en/access_results

586 GWAS summary statistics for CWP are available from

587 <https://zenodo.org/record/4459546>

588 GWAS summary statistics for IBS are available from

589 http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90044001-

590 [GCST90045000/GCST90044107/](http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90044001-GCST90045000/GCST90044107/)

591 GWAS summary statistics for TMJ are available from

592 http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90016001-

593 [GCST90017000/GCST90016564/](http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90016001-GCST90017000/GCST90016564/)

594

595

596

597 **References**

- 598 1. Mills, S.E.E., Nicolson, K.P., and Smith, B.H. (2019). Chronic pain: a review of its
599 epidemiology and associated factors in population-based studies. *Br. J. Anaesth.* *123*, e273–
600 e283. [10.1016/j.bja.2019.03.023](https://doi.org/10.1016/j.bja.2019.03.023).
- 601 2. Rahman, M.S., Winsvold, B.S., Chavez Chavez, S.O., Børte, S., Tsepilov, Y.A., Sharapov,
602 S.Z., HUNT All-In Pain, Aulchenko, Y.S., Hagen, K., Fors, E.A., et al. (2021). Genome-
603 wide association study identifies *RNF123* locus as associated with chronic widespread
604 musculoskeletal pain. *Ann. Rheum. Dis.* *80*, 1227–1235. [10.1136/annrheumdis-2020-
605 219624](https://doi.org/10.1136/annrheumdis-2020-219624).
- 606 3. Johnston, K.J.A., Adams, M.J., Nicholl, B.I., Ward, J., Strawbridge, R.J., Ferguson, A.,
607 McIntosh, A.M., Bailey, M.E.S., and Smith, D.J. (2019). Genome-wide association study of
608 multisite chronic pain in UK Biobank. *PLOS Genet.* *15*, e1008164.
609 [10.1371/journal.pgen.1008164](https://doi.org/10.1371/journal.pgen.1008164).
- 610 4. Tsepilov, Y.A., Freidin, M.B., Shadrina, A.S., Sharapov, S.Z., Elgaeva, E.E., Zundert, J. van,
611 Karssen, L.C., Suri, P., Williams, F.M.K., and Aulchenko, Y.S. (2020). Analysis of
612 genetically independent phenotypes identifies shared genetic factors associated with chronic
613 musculoskeletal pain conditions. *Commun. Biol.* *3*, 329. [10.1038/s42003-020-1051-9](https://doi.org/10.1038/s42003-020-1051-9).
- 614 5. Johnston, K.J.A., Ward, J., Ray, P.R., Adams, M.J., McIntosh, A.M., Smith, B.H.,
615 Strawbridge, R.J., Price, T.J., Smith, D.J., Nicholl, B.I., et al. (2021). Sex-stratified genome-
616 wide association study of multisite chronic pain in UK Biobank. *PLOS Genet.* *17*, e1009428.
617 [10.1371/journal.pgen.1009428](https://doi.org/10.1371/journal.pgen.1009428).
- 618 6. Farrell, S.F., Campos, A.I., Kho, P.-F., de Zoete, R.M.J., Sterling, M., Rentería, M.E., Ngo,
619 T.T., and Cuéllar-Partida, G. (2021). Genetic basis to structural grey matter associations with
620 chronic pain. *Brain J. Neurol.* *144*, 3611–3622. [10.1093/brain/awab334](https://doi.org/10.1093/brain/awab334).
- 621 7. Ghani, M., Reitz, C., Cheng, R., Vardarajan, B.N., Jun, G., Sato, C., Naj, A., Rajbhandary,
622 R., Wang, L.-S., Valladares, O., et al. (2015). Association of Long Runs of Homozygosity
623 With Alzheimer Disease Among African American Individuals. *JAMA Neurol.* *72*, 1313–
624 1323. [10.1001/jamaneurol.2015.1700](https://doi.org/10.1001/jamaneurol.2015.1700).
- 625 8. Nicholas, M., Vlaeyen, J.W.S., Rief, W., Barke, A., Aziz, Q., Benoliel, R., Cohen, M., Evers,
626 S., Giamberardino, M.A., Goebel, A., et al. (2019). The IASP classification of chronic pain
627 for ICD-11: chronic primary pain. *Pain* *160*, 28–37. [10.1097/j.pain.0000000000001390](https://doi.org/10.1097/j.pain.0000000000001390).
- 628 9. Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., Cohen, M., Evers,
629 S., Finnerup, N.B., First, M.B., et al. (2019). Chronic pain as a symptom or a disease: the
630 IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-
631 11). *Pain* *160*, 19–27. [10.1097/j.pain.0000000000001384](https://doi.org/10.1097/j.pain.0000000000001384).
- 632 10. IASP Announces Revised Definition of Pain Int. Assoc. Study Pain IASP. [https://www.iasp-
633 pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/](https://www.iasp-pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/).

- 634 11. Yong, R.J., Mullins, P.M., and Bhattacharyya, N. (2022). Prevalence of chronic pain among
635 adults in the United States. *PAIN* 163, e328. 10.1097/j.pain.0000000000002291.
- 636 12. Global, regional, and national burden of 12 mental disorders in 204 countries and territories,
637 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022).
638 *Lancet Psychiatry* 9, 137–150. 10.1016/S2215-0366(21)00395-3.
- 639 13. Terminology | International Association for the Study of Pain Int. Assoc. Study Pain IASP.
640 <https://www.iasp-pain.org/resources/terminology/>.
- 641 14. Fitzcharles, M.-A., Cohen, S.P., Clauw, D.J., Littlejohn, G., Usui, C., and Häuser, W. (2021).
642 Nociceptive pain: towards an understanding of prevalent pain conditions. *The Lancet* 397,
643 2098–2110. 10.1016/S0140-6736(21)00392-5.
- 644 15. Maixner, W., Fillingim, R.B., Williams, D.A., Smith, S.B., and Slade, G.D. (2016).
645 Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification. *J. Pain*
646 17, T93–T107. 10.1016/j.jpain.2016.06.002.
- 647 16. Schrepf, A., Phan, V., Clemens, J.Q., Maixner, W., Hanauer, D., and Williams, D.A. (2020).
648 ICD-10 Codes for the Study of Chronic Overlapping Pain Conditions in Administrative
649 Databases. *J. Pain* 21, 59–70. 10.1016/j.jpain.2019.05.007.
- 650 17. Till, S.R., Schrepf, A., Clauw, D.J., Harte, S.E., Williams, D.A., and As-Sanie, S. (2023).
651 Association Between Nociceptive Pain and Pain Severity and Impact in Women With
652 Chronic Pelvic Pain. *J. Pain*, S1526-5900(23)00369-3. 10.1016/j.jpain.2023.03.004.
- 653 18. Harte, S.E., Harris, R.E., and Clauw, D.J. (2018). The neurobiology of central sensitization.
654 *J. Appl. Biobehav. Res.* 23, e12137. 10.1111/jabr.12137.
- 655 19. Schrepf, A., Gallop, R., Naliboff, B., Harte, S.E., Afari, N., Lai, H.H., Pontari, M.,
656 McKernan, L.C., Strachan, E., Kreder, K.J., et al. (2022). Clinical Phenotyping for Pain
657 Mechanisms in Urologic Chronic Pelvic Pain Syndromes: A MAPP Research Network
658 Study. *J. Pain* 23, 1594–1603. 10.1016/j.jpain.2022.03.240.
- 659 20. Jr, L., Da, W., Ms, L., Dj, C., Bd, N., Na, R., A, van B., S, S., Aj, S., Lv, R., et al. (2014).
660 The MAPP research network: design, patient characterization and operations. *BMC Urol.* 14.
661 10.1186/1471-2490-14-58.
- 662 21. Neblett, R., Cohen, H., Choi, Y., Hartzell, M., Williams, M., Mayer, T.G., and Gatchel, R.J.
663 (2013). THE CENTRAL SENSITIZATION INVENTORY (CSI): ESTABLISHING
664 CLINICALLY-SIGNIFICANT VALUES FOR IDENTIFYING CENTRAL SENSITIVITY
665 SYNDROMES IN AN OUTPATIENT CHRONIC PAIN SAMPLE. *J. Pain Off. J. Am. Pain*
666 *Soc.* 14, 438–445. 10.1016/j.jpain.2012.11.012.
- 667 22. Ghavidel-Parsa, B., Bidari, A., Atrkarroushan, Z., and Khosousi, M. (2021). Implication of
668 the Nociceptive Features for Clinical Diagnosis of Fibromyalgia: Development of the
669 Preliminary Nociceptive-Based Fibromyalgia Features (NFF) Tool. *ACR Open Rheumatol.*
670 4, 260–268. 10.1002/acr2.11390.

- 671 23. Perugino, F., De Angelis, V., Pompili, M., and Martelletti, P. (2022). Stigma and Chronic
672 Pain. *Pain Ther.* 10.1007/s40122-022-00418-5.
- 673 24. Bean, D.J., Dryland, A., Rashid, U., and Tuck, N.L. (2022). The Determinants and Effects of
674 Chronic Pain Stigma: A Mixed Methods Study and the Development of a Model. *J. Pain* 23,
675 1749–1764. 10.1016/j.jpain.2022.05.006.
- 676 25. Collier, R. (2018). “Complainers, malingerers and drug-seekers” — the stigma of living with
677 chronic pain. *Can. Med. Assoc. J.* 190, E204–E205. 10.1503/cmaj.109-5553.
- 678 26. De Ruddere, L., and Craig, K.D. (2016). Understanding stigma and chronic pain: a-state-of-
679 the-art review. *Pain* 157, 1607–1610. 10.1097/j.pain.0000000000000512.
- 680 27. Quintner, J. (2020). Why Are Women with Fibromyalgia so Stigmatized? *Pain Med.* 21,
681 882–888. 10.1093/pm/pnz350.
- 682 28. Wakefield, E.O., Belamkar, V., Litt, M.D., Puhl, R.M., and Zempsky, W.T. (2021). “There’s
683 Nothing Wrong With You”: Pain-Related Stigma in Adolescents With Chronic Pain. *J.*
684 *Pediatr. Psychol.* 47, 456–468. 10.1093/jpepsy/jsab122.
- 685 29. Jackson, J.E. (2005). Stigma, liminality, and chronic pain: Mind-body borderlands. *Am.*
686 *Ethnol.* 32, 332–353. 10.1525/ae.2005.32.3.332.
- 687 30. Wakefield, E.O., Kissi, A., Mulchan, S.S., Nelson, S., and Martin, S.R. (2022). Pain-related
688 stigma as a social determinant of health in diverse pediatric pain populations. *Front. Pain*
689 *Res.* 3.
- 690 31. Samulowitz, A., Gremyr, I., Eriksson, E., and Hensing, G. (2018). “Brave Men” and
691 “Emotional Women”: A Theory-Guided Literature Review on Gender Bias in Health Care
692 and Gendered Norms towards Patients with Chronic Pain. *Pain Res. Manag.* 2018, 6358624.
693 10.1155/2018/6358624.
- 694 32. Nijs, J., Lahousse, A., Kapreli, E., Bilika, P., Saraçoğlu, İ., Malfliet, A., Coppieters, I., De
695 Baets, L., Leysen, L., Roose, E., et al. (2021). Nociceptive Pain Criteria or Recognition of
696 Central Sensitization? Pain Phenotyping in the Past, Present and Future. *J. Clin. Med.* 10,
697 3203. 10.3390/jcm10153203.
- 698 33. Marcianò, G., Vocca, C., Evangelista, M., Palleria, C., Muraca, L., Galati, C., Monea, F.,
699 Sportiello, L., De Sarro, G., Capuano, A., et al. (2023). The Pharmacological Treatment of
700 Chronic Pain: From Guidelines to Daily Clinical Practice. *Pharmaceutics* 15, 1165.
701 10.3390/pharmaceutics15041165.
- 702 34. Suri, P., Stanaway, I.B., Zhang, Y., Freidin, M.B., Tsepilov, Y.A., Carrell, D.S., Williams,
703 F.M.K., Aulchenko, Y.S., Hakonarson, H., Namjou, B., et al. (2021). Genome-wide
704 association studies of low back pain and lumbar spinal disorders using electronic health
705 record data identify a locus associated with lumbar spinal stenosis. *Pain Publish Ahead of*
706 *Print.* 10.1097/j.pain.0000000000002221.

- 707 35. Meng, W., Adams, M.J., Hebert, H.L., Deary, I.J., McIntosh, A.M., and Smith, B.H. (2018).
708 A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined
709 Headache in UK Biobank (N = 223,773). *EBioMedicine* 28, 180–186.
710 [10.1016/j.ebiom.2018.01.023](https://doi.org/10.1016/j.ebiom.2018.01.023).
- 711 36. Jiang, L., Zheng, Z., Fang, H., and Yang, J. (2021). A generalized linear mixed model
712 association tool for biobank-scale data. *Nat. Genet.* 53, 1616–1621. [10.1038/s41588-021-](https://doi.org/10.1038/s41588-021-00954-4)
713 [00954-4](https://doi.org/10.1038/s41588-021-00954-4).
- 714 37. Eijbsbouts, C., Zheng, T., Kennedy, N.A., Bonfiglio, F., Anderson, C.A., Moutsianas, L.,
715 Holliday, J., Shi, J., Shringarpure, S., 23andMe Research Team, et al. (2021). Genome-wide
716 analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways
717 with mood and anxiety disorders. *Nat. Genet.* 53, 1543–1552. [10.1038/s41588-021-00950-8](https://doi.org/10.1038/s41588-021-00950-8).
- 718 38. Hajdarevic, R., Lande, A., Mehlsen, J., Rydland, A., Sosa, D.D., Strand, E.B., Mella, O.,
719 Pociot, F., Fluge, Ø., Lie, B.A., et al. (2022). Genetic association study in myalgic
720 encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci.
721 *Brain. Behav. Immun.* 102, 362–369. [10.1016/j.bbi.2022.03.010](https://doi.org/10.1016/j.bbi.2022.03.010).
- 722 39. Grotzinger, A.D., Rhemtulla, M., de Vlaming, R., Ritchie, S.J., Mallard, T.T., Hill, W.D., Ip,
723 H.F., Marioni, R.E., McIntosh, A.M., Deary, I.J., et al. (2019). Genomic structural equation
724 modelling provides insights into the multivariate genetic architecture of complex traits. *Nat.*
725 *Hum. Behav.* 3, 513–525. [10.1038/s41562-019-0566-x](https://doi.org/10.1038/s41562-019-0566-x).
- 726 40. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R., Duncan,
727 L., Perry, J.R.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations
728 across human diseases and traits. *Nat. Genet.* 47, 1236–1241. [10.1038/ng.3406](https://doi.org/10.1038/ng.3406).
- 729 41. 2.1 Calculating Sum of Effective Sample Size and Preparing GWAS Summary Statistics ·
730 GenomicSEM/GenomicSEM Wiki · GitHub
731 [https://github.com/GenomicSEM/GenomicSEM/wiki/2.1-Calculating-Sum-of-Effective-](https://github.com/GenomicSEM/GenomicSEM/wiki/2.1-Calculating-Sum-of-Effective-Sample-Size-and-Preparing-GWAS-Summary-Statistics)
732 [Sample-Size-and-Preparing-GWAS-Summary-Statistics](https://github.com/GenomicSEM/GenomicSEM/wiki/2.1-Calculating-Sum-of-Effective-Sample-Size-and-Preparing-GWAS-Summary-Statistics).
- 733 42. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional
734 mapping and annotation of genetic associations with FUMA. *Nat. Commun.* 8, 1826.
735 [10.1038/s41467-017-01261-5](https://doi.org/10.1038/s41467-017-01261-5).
- 736 43. Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly,
737 M.J., Price, A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding
738 from polygenicity in genome-wide association studies. *Nat. Genet.* 47, 291–295.
739 [10.1038/ng.3211](https://doi.org/10.1038/ng.3211).
- 740 44. ten Klooster, P.M., de Graaf, N., and Vonkeman, H.E. (2019). Association between pain
741 phenotype and disease activity in rheumatoid arthritis patients: a non-interventional,
742 longitudinal cohort study. *Arthritis Res. Ther.* 21, 257. [10.1186/s13075-019-2042-4](https://doi.org/10.1186/s13075-019-2042-4).

- 743 45. Cao, Y., Fan, D., and Yin, Y. (2020). Pain Mechanism in Rheumatoid Arthritis: From
744 Cytokines to Central Sensitization. *Mediators Inflamm.* 2020, 2076328.
745 10.1155/2020/2076328.
- 746 46. Veluchamy, A., Hébert, H.L., van Zuydam, N.R., Pearson, E.R., Campbell, A., Hayward, C.,
747 Meng, W., McCarthy, M.I., Bennett, D.L.H., Palmer, C.N.A., et al. (2021). Association of
748 Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. *JAMA*
749 *Netw. Open* 4, e2136560. 10.1001/jamanetworkopen.2021.36560.
- 750 47. Ha, E., Bae, S.-C., and Kim, K. (2021). Large-scale meta-analysis across East Asian and
751 European populations updated genetic architecture and variant-driven biology of rheumatoid
752 arthritis, identifying 11 novel susceptibility loci. *Ann. Rheum. Dis.* 80, 558–565.
753 10.1136/annrheumdis-2020-219065.
- 754 48. Sollis, E., Mosaku, A., Abid, A., Buniello, A., Cerezo, M., Gil, L., Groza, T., Güneş, O.,
755 Hall, P., Hayhurst, J., et al. (2023). The NHGRI-EBI GWAS Catalog: knowledgebase and
756 deposition resource. *Nucleic Acids Res.* 51, D977–D985. 10.1093/nar/gkac1010.
- 757 49. Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., de Geus,
758 E.J., Boomsma, D.I., Wright, F.A., et al. (2016). Integrative approaches for large-scale
759 transcriptome-wide association studies. *Nat. Genet.* 48, 245–252. 10.1038/ng.3506.
- 760 50. The GTEx Consortium atlas of genetic regulatory effects across human tissues (2020). 15.
- 761 51. TWAS / FUSION [http://gusevlab.org/projects/fusion/#download-pre-computed-predictive-](http://gusevlab.org/projects/fusion/#download-pre-computed-predictive-models)
762 [models.](http://gusevlab.org/projects/fusion/#download-pre-computed-predictive-models)
- 763 52. Kosek, E., Clauw, D., Nijs, J., Baron, R., Gilron, I., Harris, R.E., Mico, J.-A., Rice, A.S.C.,
764 and Sterling, M. (2021). Chronic nociplastic pain affecting the musculoskeletal system:
765 clinical criteria and grading system. *PAIN* 162, 2629. 10.1097/j.pain.0000000000002324.
- 766 53. Bailly, F., Cantagrel, A., Bertin, P., Perrot, S., Thomas, T., Lansaman, T., Grange, L.,
767 Wendling, D., Dovico, C., and Trouvin, A.-P. (2020). Part of pain labelled neuropathic in
768 rheumatic disease might be rather nociplastic. *RMD Open* 6, e001326. 10.1136/rmdopen-
769 2020-001326.
- 770 54. Woods, R.H. (2022). Alopecia signals associated with calcitonin gene-related peptide
771 inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study.
772 *Pharmacother. J. Hum. Pharmacol. Drug Ther.* 42, 758–767. 10.1002/phar.2725.
- 773 55. Aroke, E.N., and Powell-Roach, K.L. (2020). The Metabolomics of Chronic Pain
774 Conditions: A Systematic Review. *Biol. Res. Nurs.* 22, 458–471.
775 10.1177/1099800420941105.
- 776 56. Boyd, J.T., LoCoco, P.M., Furr, A.R., Bendele, M.R., Tram, M., Li, Q., Chang, F.-M.,
777 Colley, M.E., Samenuk, G.M., Arris, D.A., et al. (2021). Elevated dietary ω -6
778 polyunsaturated fatty acids induce reversible peripheral nerve dysfunction that exacerbates
779 comorbid pain conditions. *Nat. Metab.* 3, 762–773. 10.1038/s42255-021-00410-x.

- 780 57. Chiurchiù, V., Leuti, A., and Maccarrone, M. (2018). Bioactive Lipids and Chronic
781 Inflammation: Managing the Fire Within. *Front. Immunol.* 9.
- 782 58. Li, S., Gao, D., and Jiang, Y. (2019). Function, Detection and Alteration of Acylcarnitine
783 Metabolism in Hepatocellular Carcinoma. *Metabolites* 9, 36. 10.3390/metabo9020036.
- 784 59. Sanders, A.E., Weatherspoon, E.D., Ehrmann, B.M., Soma, P.S., Shaikh, S.R., Preisser, J.S.,
785 Ohrbach, R., Fillingim, R.B., and Slade, G.D. (2022). Circulating polyunsaturated fatty
786 acids, pressure pain thresholds, and nociplastic pain conditions. *Prostaglandins Leukot.*
787 *Essent. Fatty Acids* 184, 102476. 10.1016/j.plefa.2022.102476.
- 788 60. Navia-Pelaez, J.M., Choi, S.-H., dos Santos Aggum Capettini, L., Xia, Y., Gonen, A.,
789 Agatista-Boyle, C., Delay, L., Gonçalves dos Santos, G., Catroli, G.F., Kim, J., et al. (2021).
790 Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain. *J.*
791 *Exp. Med.* 218, e20202059. 10.1084/jem.20202059.
- 792 61. Robinson, G., Pineda-Torra, I., Ciurtin, C., and Jury, E.C. (2022). Lipid metabolism in
793 autoimmune rheumatic disease: implications for modern and conventional therapies. *J. Clin.*
794 *Invest.* 132. 10.1172/JCI148552.
- 795 62. Elma, Ö., Brain, K., and Dong, H.-J. (2022). The Importance of Nutrition as a Lifestyle
796 Factor in Chronic Pain Management: A Narrative Review. *J. Clin. Med.* 11, 5950.
797 10.3390/jcm11195950.
- 798 63. Xiang, C., Chen, C., Li, X., Wu, Y., Xu, Q., Wen, L., Xiong, W., Liu, Y., Zhang, T., Dou,
799 C., et al. (2022). Computational approach to decode the mechanism of curcuminoids against
800 neuropathic pain. *Comput. Biol. Med.* 147, 105739. 10.1016/j.compbimed.2022.105739.
- 801 64. Armstrong, C.W., McGregor, N.R., Butt, H.L., and Gooley, P.R. (2014). Chapter Five -
802 Metabolism in Chronic Fatigue Syndrome. In *Advances in Clinical Chemistry*, G. S.
803 Makowski, ed. (Elsevier), pp. 121–172. 10.1016/B978-0-12-801401-1.00005-0.
- 804 65. Hoel, F., Hoel, A., Pettersen, I.K.N., Rekeland, I.G., Risa, K., Alme, K., Sørland, K., Fosså,
805 A., Lien, K., Herder, I., et al. A map of metabolic phenotypes in patients with myalgic
806 encephalomyelitis/chronic fatigue syndrome. *JCI Insight* 6, e149217.
807 10.1172/jci.insight.149217.
- 808 66. Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Sonmez, T., Coker, D., Symons,
809 A., Esparza-Gordillo, J., Aslibekyan, S., and Auton, A. (2021). Trans-ancestry analysis
810 reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. *Nat.*
811 *Genet.* 53, 801–808. 10.1038/s41588-021-00854-7.
- 812 67. Yang, Z., Zhou, D., Li, H., Cai, X., Liu, W., Wang, L., Chang, H., Li, M., and Xiao, X.
813 (2020). The genome-wide risk alleles for psychiatric disorders at 3p21.1 show convergent
814 effects on mRNA expression, cognitive function, and mushroom dendritic spine. *Mol.*
815 *Psychiatry* 25, 48–66. 10.1038/s41380-019-0592-0.

- 816 68. Mei, Q., Li, X., Zhang, K., Wu, Z., Li, X., Meng, Y., Guo, M., Luo, G., Fu, X., and Han, W.
817 (2017). Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3
818 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling
819 Pathway. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* *23*, 575–586. [10.1158/1078-0432.CCR-16-0303](https://doi.org/10.1158/1078-0432.CCR-16-0303).
- 821 69. Ortiz, M., Towfic, F., Flynt, E., Stong, N., Lata, S., Sampath, D., Rozelle, D., Trotter, M.,
822 Corre, J., Avet-Loiseau, H., et al. (2019). Gene Expression and Genomic Markers Identify a
823 Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma.
824 *Blood* *134*, 366. [10.1182/blood-2019-128907](https://doi.org/10.1182/blood-2019-128907).
- 825 70. Gunther, K., Mowrey, K., and Farach, L.S. (2021). Two new reported cases of 16q22.3q23.3
826 duplication syndrome highlight intrafamilial variability and potential sex expression
827 differences within a rare duplication syndrome. *Clin. Case Rep.* *9*, 1629–1633.
828 [10.1002/ccr3.3862](https://doi.org/10.1002/ccr3.3862).
- 829 71. Bozorgmehr, A., Sadeghi, B., Tabatabaei Zavari, E.S., Bahrami, E., Zamani, F., and
830 Shahbazi, A. (2020). An integrative gene network-based approach to uncover the cellular
831 and molecular infrastructures of schizophrenia. *Life Sci.* *260*, 118345.
832 [10.1016/j.lfs.2020.118345](https://doi.org/10.1016/j.lfs.2020.118345).
- 833 72. Ahmed, H., Akbari, H., Emami, A., and Akbari, M.R. (2017). Genetic Overview of
834 Syndactyly and Polydactyly. *Plast. Reconstr. Surg. Glob. Open* *5*, e1549.
835 [10.1097/GOX.0000000000001549](https://doi.org/10.1097/GOX.0000000000001549).
- 836 73. Li, Y.R., Glessner, J.T., Coe, B.P., Li, J., Mohebnasab, M., Chang, X., Connolly, J., Kao, C.,
837 Wei, Z., Bradfield, J., et al. (2020). Rare copy number variants in over 100,000 European
838 ancestry subjects reveal multiple disease associations. *Nat. Commun.* *11*, 255.
839 [10.1038/s41467-019-13624-1](https://doi.org/10.1038/s41467-019-13624-1).
- 840 74. Åkesson, K., Tenne, M., Gerdhem, P., Luthman, H., and McGuigan, F.E. (2015). Variation
841 in the PTH2R gene is associated with age-related degenerative changes in the lumbar spine.
842 *J. Bone Miner. Metab.* *33*, 9–15. [10.1007/s00774-013-0550-x](https://doi.org/10.1007/s00774-013-0550-x).
- 843 75. LITTLETON, S.H., BRADFIELD, J., PIPPIN, J.A., SU, C., CHESI, A., WELLS, A.D.,
844 BERKOWITZ, R.I., PAHL, M.C., and GRANT, S.F. (2022). 298-OR: Variant-to-Gene
845 Mapping at the Childhood Obesity Locus on chr12q13 and Subsequent Luciferase Assay
846 Analyses Implicate rs71329as a Causal Variant within the 3' UTR of FAIM2. *Diabetes* *71*,
847 298-OR. [10.2337/db22-298-OR](https://doi.org/10.2337/db22-298-OR).
- 848 76. Daya, M., Rafaels, N., Brunetti, T.M., Chavan, S., Levin, A.M., Shetty, A., Gignoux, C.R.,
849 Boorgula, M.P., Wojcik, G., Campbell, M., et al. (2019). Association study in African-
850 admixed populations across the Americas recapitulates asthma risk loci in non-African
851 populations. *Nat. Commun.* *10*, 880. [10.1038/s41467-019-08469-7](https://doi.org/10.1038/s41467-019-08469-7).
- 852 77. Demenais, F., Margaritte-Jeannin, P., Barnes, K.C., Cookson, W.O., Altmüller, J., Ang, W.,
853 Barr, R.G., Beaty, T.H., Becker, A.B., Beilby, J., et al. (2018). Multiancestry association

- 854 study identifies new asthma risk loci that colocalize with immune cell enhancer marks. *Nat.*
855 *Genet.* *50*, 42–53. [10.1038/s41588-017-0014-7](https://doi.org/10.1038/s41588-017-0014-7).
- 856 78. CHARGE Inflammation working group, Ahluwalia, T.S., Prins, B.P., Abdollahi, M.,
857 Armstrong, N.J., Aslibekyan, S., Bain, L., Jefferis, B., Baumert, J., Beekman, M., et al.
858 (2021). Genome-wide association study of circulating interleukin 6 levels identifies novel
859 loci. *Hum. Mol. Genet.* *30*, 393–409. [10.1093/hmg/ddab023](https://doi.org/10.1093/hmg/ddab023).
- 860 79. Bergmans, R.S., Clauw, D.J., Flint, C., Harris, H., Lederman, S., and Schrepf, A. (2024).
861 Chronic overlapping pain conditions increase the risk of long COVID features, regardless of
862 acute COVID status. *PAIN* *165*, 1112. [10.1097/j.pain.0000000000003110](https://doi.org/10.1097/j.pain.0000000000003110).
- 863 80. Wong, D., Auguste, G., Lino Cardenas, C.L., Turner, A.W., Chen, Y., Song, Y., Ma, L.,
864 Perry, R.N., Aherrahrou, R., Kuppusamy, M., et al. (2023). FHL5 Controls Vascular
865 Disease-Associated Gene Programs in Smooth Muscle Cells. *Circ. Res.* *132*, 1144–1161.
866 [10.1161/CIRCRESAHA.122.321692](https://doi.org/10.1161/CIRCRESAHA.122.321692).
- 867 81. O'Connor, E., Fourier, C., Ran, C., Sivakumar, P., Liesecke, F., Southgate, L., Harder,
868 A.V.E., Vijfhuizen, L.S., Yip, J., Giffin, N., et al. (2021). Genome-Wide Association Study
869 Identifies Risk Loci for Cluster Headache. *Ann. Neurol.* *90*, 193–202. [10.1002/ana.26150](https://doi.org/10.1002/ana.26150).
- 870 82. Atzeni, F., Cazzola, M., Benucci, M., Di Franco, M., Salaffi, F., and Sarzi-Puttini, P. (2011).
871 Chronic widespread pain in the spectrum of rheumatological diseases. *Best Pract. Res. Clin.*
872 *Rheumatol.* *25*, 165–171. [10.1016/j.berh.2010.01.011](https://doi.org/10.1016/j.berh.2010.01.011).
- 873 83. Häuser, W., Sarzi-Puttini, P., and Fitzcharles, M.-A. (2019). Fibromyalgia syndrome: under-
874 over- and misdiagnosis. *Clin. Exp. Rheumatol.* *37*, 90–97.
- 875 84. Häuser, W., Perrot, S., Sommer, C., Shir, Y., and Fitzcharles, M.-A. (2017). Diagnostic
876 confounders of chronic widespread pain: not always fibromyalgia. *Pain Rep.* *2*, e598.
877 [10.1097/PR9.0000000000000598](https://doi.org/10.1097/PR9.0000000000000598).
- 878 85. Richardson, A.C., Omar, M., Velarde, G., Missov, E., Percy, R., and Sattiraju, S. (2021).
879 Right Atrial Appendage Thrombus in Atrial Fibrillation: A Case Report and Review of the
880 Literature. *J. Investig. Med. High Impact Case Rep.* *9*, 23247096211010048.
881 [10.1177/23247096211010048](https://doi.org/10.1177/23247096211010048).
- 882 86. Regazzoli, D., Ancona, F., Trevisi, N., Guarracini, F., Radinovic, A., Oppizzi, M., Agricola,
883 E., Marzi, A., Sora, N.C., Della Bella, P., et al. (2015). Left Atrial Appendage: Physiology,
884 Pathology, and Role as a Therapeutic Target. *BioMed Res. Int.* *2015*, 205013.
885 [10.1155/2015/205013](https://doi.org/10.1155/2015/205013).
- 886 87. McIntyre, W.F., and Healey, J. (2017). Stroke Prevention for Patients with Atrial
887 Fibrillation: Beyond the Guidelines. *J. Atr. Fibrillation* *9*, 1475. [10.4022/jafib.1475](https://doi.org/10.4022/jafib.1475).
- 888 88. Peuckmann-Post, V., Eickhoff, R., Becker, M., and von der Laage, D. (2012). [ECG changes
889 in patients with chronic non-cancer pain: a prospective observational study]. *Schmerz Berl.*
890 *Ger.* *26*, 419–424. [10.1007/s00482-012-1204-y](https://doi.org/10.1007/s00482-012-1204-y).

- 891 89. Gong, C., Ding, Y., Liang, F., Wu, S., Tang, X., Ding, H., Huang, W., Yu, X., Zhou, L., Li,
892 J., et al. (2022). Muscarinic receptor regulation of chronic pain-induced atrial fibrillation.
893 *Front. Cardiovasc. Med.* 9, 934906. [10.3389/fcvm.2022.934906](https://doi.org/10.3389/fcvm.2022.934906).
- 894 90. McIntyre, W.F., Connolly, S.J., and Healey, J.S. (2018). Atrial fibrillation occurring
895 transiently with stress. *Curr. Opin. Cardiol.* 33, 58–65. [10.1097/HCO.0000000000000475](https://doi.org/10.1097/HCO.0000000000000475).
- 896 91. McIntyre, W.F., Um, K.J., Cheung, C.C., Belley-Côté, E.P., Dingwall, O., Devereaux, P.J.,
897 Wong, J.A., Conen, D., Whitlock, R.P., Connolly, S.J., et al. (2019). Atrial fibrillation
898 detected initially during acute medical illness: A systematic review. *Eur. Heart J. Acute*
899 *Cardiovasc. Care* 8, 130–141. [10.1177/2048872618799748](https://doi.org/10.1177/2048872618799748).
- 900 92. Rönnegård, A.-S., Nowak, C., Äng, B., and Ärnlöv, J. (2022). The association between
901 short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease
902 in the UK Biobank. *Eur. J. Prev. Cardiol.* 29, 1994–2002. [10.1093/eurjpc/zwac127](https://doi.org/10.1093/eurjpc/zwac127).
- 903 93. Di Carlo, M., Bianchi, B., Cipolletta, E., Farah, S., Filippucci, E., and Salaffi, F. Imaging of
904 the peripheral nervous system in nociplastic pain: An ultrasound study in patients with
905 fibromyalgia. *J. Neuroimaging* *n/a*. [10.1111/jon.13104](https://doi.org/10.1111/jon.13104).
- 906 94. JO, Y.-S., YOON, B., HONG, J.Y., JOUNG, C.-I., KIM, Y., and NA, S.-J. (2021). Tarsal
907 tunnel syndrome in patients with fibromyalgia. *Arch. Rheumatol.* 36, 107–113.
908 [10.46497/ArchRheumatol.2021.7952](https://doi.org/10.46497/ArchRheumatol.2021.7952).
- 909 95. Xiang, H., Zhang, T., Al-Danakh, A., Yang, D., and Wang, L. (2022). Neuromodulation in
910 Chronic Pelvic Pain: A Narrative Review. *Pain Ther.* 11, 789–816. [10.1007/s40122-022-00405-w](https://doi.org/10.1007/s40122-022-00405-w).
- 912
- 913

914 **Figure Titles and Legends**

915 **Figure 1: Path diagram of common factor GWAS GenomicSEM model.**

916 Values = Standardized Estimate (Standard Error).

917 **Figure 2: Manhattan plot of nociplastic-type pain common-factor GWAS and**
918 **multivariate TWAS outputs.**

919 A: Nociplastic-type pain – common-factor GWAS Manhattan plot. Dotted line = genome-
920 wide p value significance threshold ($-\log_{10}(5 \times 10^{-8})$). B: Nociplastic-type pain –
921 multivariate TWAS Manhattan plot. X-axis labels = GTEx v8 tissue, points shown in
922 orange = gene-tissue associations significant after Bonferroni adjustment within that
923 tissue, labeled points = genes with most significant association within that tissue.

924 **Figure 3: GWAS catalog trait gene set enrichments.**

925 A: Gene sets enriched for all nociplastic-type pain genes found in multivariate TWAS
926 analysis, B: Gene sets enriched for specific nociplastic type pain genes, Panel C: Gene
927 sets enriched for non-specific nociplastic type pain genes.

928

Trait	Acronym	Source	Cases	Controls
Chronic widespread pain	CWP	Rahman et al 2021 ²	6914	242929
Endometriosis	NA	FinnGenn (R9, May 2023)	15088	107564
Low-back pain	LBP	Suri et al 2021 ³⁴	49182	51629
Broad headache	NA	Meng et al 2018 ³⁵	74461	149312
Temporomandibular joint disorder	TMJ	Jiang et al 2021 (GWAS Catalog) ³⁶	217	456131

Irritable Bowel Syndrome	IBS	Eijsbouts et al 2021 (GWAS Catalog) ³⁷	53400	433201
--------------------------	-----	---	-------	--------

929 **Table 1: Sources and sample sizes for COPC trait GWAS.** See Table S1 for sample
930 and population prevalence estimates and their sources.

931

Trait	Standardized Estimate	Standardized SE	p-value
CWP	0.76	0.06	1.78×10^{-41}
IBS	0.62	0.03	3.87×10^{-73}
Broad Headache	0.73	0.04	4.56×10^{-81}
LBP	0.39	0.04	5.53×10^{-28}
TMJ	0.69	0.29	0.0188
Endometriosis	0.57	0.06	3.34×10^{-20}

932 **Table 2: Standardized common-factor GWAS model factor loadings and p values.**

933 SE = standard error.

934

Nociplastic
Pain

```
graph TD; NP[Nociplastic Pain] --- CWP((CWP)); NP --- IBS((IBS)); NP --- Headache((Headache)); NP --- LBP((LBP)); NP --- TMJ((TMJ)); NP --- Endo((Endo));
```

CWP

IBS

Headache

LBP

TMJ

Endo

